期刊
ANTIVIRAL RESEARCH
卷 89, 期 1, 页码 75-82出版社
ELSEVIER
DOI: 10.1016/j.antiviral.2010.11.007
关键词
Interferon; mDEF201; SARS; Treatment; Prophylaxis
资金
- Virology Branch, National Institute of Allergic and Infectious Diseases, National Institutes of Health [N01-AI-15435]
- AES [538]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015435] Funding Source: NIH RePORTER
Interferons (IFNs) are a first line of defense against viral infection. Herein we describe the use of an adenovirus vectored mouse IFN alpha gene (mDEF201) as a prophylactic and treatment countermeasure in a SARS-CoV-infected BALB/c mouse model. Complete survival protection was observed in mice given a single dose of mDEF201 administered intranasally 1, 3, 5, 7, or 14 days prior to lethal SARS-CoV challenge (p < 0.001), and body weights of these treated mice were unaffected by the challenge. In addition, low doses of mDEF201 protected lungs in a dose dependent manner as measured by a reduction in gross pathology. Intranasal treatment with mDEF201 ranging from 10(6) to 10(8) PFU significantly protected mice against a lethal SARS-CoV infection in a dose dependent manner up to 12 h post infection (p < 0.001). The data suggest that mDEF201 is a new class of antiviral agent further development as treatment for SARS-CoV infections. (C) 2010 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据